>

Mary Coleman - Johnson Johnson Independent Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 40px;;'>JNJ</div>
JNJ -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  Director
Dr. Mary Sue Coleman, Ph.D. is an Independent Director of the company. She joined the Board of Directors in 2003 and is a member of the Audit Committee and the Science, Technology Sustainability Committee. She is President Emerita of the University of Michigan, having served as President from August 2002 to July 2014. She also was a Professor of Biological Chemistry in the University of Michigan Medical School and a Professor of Chemistry in the University of Michigan College of Literature, Science and the Arts. From 1995 to July 2002, Dr. Coleman served as President of the University of Iowa. Prior to 1995, Dr. Coleman served as Provost and Vice President for Academic Affairs at the University of New Mexico, Vice Chancellor for Graduate Studies Research and Associate Provost and Dean of Research at the University of North Carolina at Chapel Hill, and a member of the biochemistry faculty and an administrator at the Cancer Center of the University of Kentucky in Lexington. Elected to the National Academy of Sciences Institute of Medicine in 1997, Dr. Coleman is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science. Dr. Coleman is a Trustee of the Gerald R. Ford Foundation, the Gates Cambridge Scholarship program, and the Mayo Clinic Foundation, and is on the Board of Directors of The Kavli Foundation.
Age: 70  Director Since 2003      
732 214-0332  www.jnj.com

Mary Coleman Latest Insider Activity

Mary Coleman over three weeks ago via Macroaxis 
Meredith exotic insider transaction detected
Mary Coleman over two months ago via Macroaxis 
Meredith exotic insider transaction detected
Mary Coleman over three months ago via Macroaxis 
Meredith exotic insider transaction detected
Mary Coleman over three months ago via Macroaxis 
Acquisition or disposition of Johnson Johnson securities by Mary Coleman

Management Efficiency

The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Laurie GlimcherGlaxoSmithKline PLC
2017
Wendell WeeksMerck Company
2004
Shantanu NarayenPfizer
2013
Harish ManwaniGilead Sciences
2018
Simon DingemansGlaxoSmithKline PLC
2011
Michael GrobsteinBristol Myers Squibb Company
2007
Per WoldOlsenGilead Sciences
2010
Carlos RepresasMerck Company
2009
Don CornwellPfizer
1997
Pamela CraigMerck Company
2015
David HooverEli Lilly And Company
2009
Ton BuechnerNovartis AG
2016
Marschall RungeEli Lilly And Company
2013
Dennis AusielloPfizer
2015
Hans WijersGlaxoSmithKline PLC
2013
Urs RohnerGlaxoSmithKline PLC
2015
Robert KidderMerck Company
2005
Etienne DavignonGilead Sciences
N/A
James SmithPfizer
2014
Ellen MarramEli Lilly And Company
2013
Paul RothmanMerck Company
2015

Company Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent DirectorView
Jennifer Doudna, Independent DirectorView
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. CommitteeView
William Perez, Independent DirectorView
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication OfficerView
Marillyn Hewson, Independent DirectorView
Jorge Mesquita, Executive Vice President Worldwide Chairman - ConsumerView
Mary Coleman, Independent DirectorView
Michael Ullmann, VP, General Counsel and Member of Executive CommitteeView
Joaquin Duato, Executive Vice President Worldwide Chairman - PharmaceuticalsView
Kathy Wengel, Executive Vice President Chief Global Supply Chain OfficerView
Jennifer Taubert, Executive Vice President - Worldwide Chairman, PharmaceuticalsView
Mary Beckerle, Independent DirectorView
Sandra Peterson, Group Worldwide Chairman and Member of Executive CommitteeView
Scott Davis, DirectorView
Louise Mehrotra, Vice President Investor RelationsView
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical DevicesView
Ronald Williams, Independent DirectorView
Kathryn Wengel, Executive Vice President Chief Global Supply Chain OfficerView
D Davis, Independent DirectorView
Hubert Joly, DirectorView
Anne Mulcahy, Lead Independent DirectorView
Joseph Wolk, Chief Financial Officer, Executive Vice PresidentView
Thibaut Mongon, Executive Vice President Worldwide Chairman, ConsumerView
Ian Davis, Independent DirectorView
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive CommitteeView
Mark McClellan, Independent DirectorView
Charles Prince, Independent DirectorView
Eugene Washington, Independent DirectorView
Dominic Caruso, CFO, VP of Fin. and Member of Executive CommitteeView
Peter Fasolo, Chief Human Resource Officer, Executive Vice PresidentView
Susan Lindquist, Independent DirectorView
Mark Weinberger, DirectorView

Stock Performance Indicators

Did you try this?

Run Stock Screener Now

   

Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.